Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355151 | 1.00 | MEN1 (0.49) | MEN1KMT2APABPC1BCL2POLB | |
| SCHEMBL1478400 | 0.85 | L3MBTL1 (0.40) | ALDH1A1 | |
| SCHEMBL1478396 | 0.85 | L3MBTL1 (0.40) | ALDH1A1 | |
| SCHEMBL12749279 | 0.85 | L3MBTL1 (0.40) | ALDH1A1 | |
| SCHEMBL1478395 | 0.85 | L3MBTL1 (0.40) | ALDH1A1 | |
| SCHEMBL10900104 | 0.85 | BCL2 (0.47) | MEN1KMT2APABPC1BCL2POLB | |
| SCHEMBL17107533 | 0.82 | HCRTR2 (0.42) | ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL12827760 | 0.82 | TSHR (0.47) | MEN1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL1478271 | 0.82 | TSHR (0.47) | MEN1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL1477903 | 0.82 | TSHR (0.47) | MEN1KMT2APOLBALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | ADRA2C, ADRB2, ADRA2A | MEN1 4412/4885KMT2A 4242/4885PABPC1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.